Congenital Adrenal Hyperplasia Treatment Panel
Ordering Recommendation

Use to monitor treatment of individuals with classic or nonclassic congenital adrenal hyperplasia.

Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Collect between 6-10 a.m. 
Serum separator tube or green (sodium or lithium heparin). Also acceptable: Pink (K2EDTA). 
Specimen Preparation
Transfer 1.2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.7 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months 
Reference Interval
Test Number
Reference Interval
2001638AndrostenedioneEffective August 19, 2013
Premature Infants, 26-28 weeks-Day 40.92-2.82 ng/mL0.92-2.82 ng/mL
Premature Infants, 31-35 weeks-Day 40.80-4.46 ng/mL0.80-4.46 ng/mL
Full-term Infants, 1-7 days0.20-2.90 ng/mL0.20-2.90 ng/mL
8-30 days0.18-0.80 ng/mL0.18-0.80 ng/mL
1-5 months0.06-0.68 ng/mL0.06-0.68 ng/mL
6-24 monthsLess than 0.15 ng/mL0.03-0.15 ng/mL
2-3 yearsLess than 0.16 ng/mLLess than 0.11 ng/mL
4-5 years0.02-0.21 ng/mL0.02-0.17 ng/mL
6-7 years0.02-0.28 ng/mL0.01-0.29 ng/mL
8-9 years0.04-0.42 ng/mL0.03-0.30 ng/mL
10-11 years0.09-1.23 ng/mL0.07-0.39 ng/mL
12-13 years0.24-1.73 ng/mL0.10-0.64 ng/mL
14-15 years0.39-2.00 ng/mL0.18-0.94 ng/mL
16-17 years0.35-2.12 ng/mL0.30-1.13 ng/mL
18-39 years0.26-2.14 ng/mL0.33-1.34 ng/mL
40 years and older0.13-0.82 ng/mL0.23-0.89 ng/mL
Pre-menopausal0.26-2.14 ng/mLDoes Not Apply
Postmenopausal0.13-0.82 ng/mLDoes Not Apply
Tanner Stage I0.05-0.51 ng/mL0.04-0.32 ng/mL
Tanner Stage II0.15-1.37 ng/mL0.08-0.48 ng/mL
Tanner Stage III0.37-2.24 ng/mL0.14-0.87 ng/mL
Tanner Stage IV-V0.35-2.05 ng/mL0.27-1.07 ng/mL

009233217-Hydroxyprogesterone Quantitative by HPLC-MS/MS, Serum or PlasmaEffective August 19, 2013
Premature (26-28 weeks)124-841 ng/dL124-841 ng/dL
Premature (29-35 weeks)26-568 ng/dL26-568 ng/dL
Full term Day 37-77 ng/dL7-77 ng/dL
4 days-30 days7-106 ng/dLLess than 200 ng/dL
1 month-2 months13-106 ng/dLLess than 200 ng/dL
3 months-5 months13-106 ng/dL3-90 ng/dL
6  months-1 yearLess than or equal to 148 ng/dLLess than or equal to 148 ng/dL
2-3 yearsLess than or equal to 256 ng/dLLess than or equal to 228 ng/dL
4-6 yearsLess than or equal to 299 ng/dLLess than or equal to 208 ng/dL
7-9 yearsLess than or equal to 71 ng/dLLess than or equal to 63 ng/dL
10-12 yearsLess than or equal to 129 ng/dLLess than or equal to 79 ng/dL
13-15 years9-208 ng/dL9-140 ng/dL
16-17 yearsLess than or equal to 178 ng/dL24-192 ng/dL
18 years and olderLess than 207 ng/dLLess than 139 ng/dL
Follicular15-70 ng/dLDoes Not Apply
Luteal35-290 ng/dLDoes Not Apply
Tanner Stage ILess than or equal to 74 ng/dLLess than or equal to 62 ng/dL
Tanner Stage IILess than or equal to 164 ng/dLLess than or equal to 104 ng/dL
Tanner Stage III13-209 ng/dLLess than or equal to 151 ng/dL
Tanner Stage IV-V7-170 ng/dL20-173 ng/dL

0081058Testosterone, Females or ChildrenEffective August 19, 2013
Premature (26-28 weeks)5-16 ng/dL59-125 ng/dL
Premature (31-35 weeks)5-22 ng/dL37-198 ng/dL
Newborn20-64 ng/dL75-400 ng/dL
1-5 monthsLess than 20 ng/dL14-363 ng/dL
6-24 monthsLess than 9 ng/dLLess than 37 ng/dL
2-3 yearsLess than 20 ng/dLLess than 15 ng/dL
4-5 yearsLess than 30 ng/dLLess than 19 ng/dL
6-7 yearsLess than 7 ng/dLLess than 13 ng/dL
8-9 years1-11ng/dL2-8 ng/dL
10-11 years3-32 ng/dL2-165 ng/dL
12-13 years6-50 ng/dL3-619 ng/dL
14-15 years6-52 ng/dL31-733 ng/dL
16-17 years9-58 ng/dL158-826 ng/dL
18-39 years9-55 ng/dL300-1080 ng/dL
40-59 years9-55 ng/dL300-890 ng/dL
60 years and older5-32 ng/dL300-720 ng/dL
Premenopausal (18 years and older)9-55 ng/dLDoes Not Apply
Postmenopausal5-32 ng/dLDoes Not Apply
Tanner Stage I2-17 ng/dL2-15 ng/dL
Tanner Stage II5-40 ng/dL3-303 ng/dL
Tanner Stage III10-63 ng/dL10-851 ng/dL
Tanner Stage IV-V11-62 ng/dL162-847 ng/dL

Interpretive Data
Total testosterone values may not reflect optimal concentrations in all individuals. Free or bioavailable testosterone measurements may provide supportive information.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
CPT Code(s)
Component Test Code*Component Chart NameLOINC
0081058Testosterone, LC-MS/MS2986-8
009233217-Hydroxyprogesterone, HPLC-MS/MS1668-3
2001639Androstenedione by TMS1854-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • 17-Hydroxyprogesterone (Congenital Adrenal Hyperplasia Treatment Panel)
  • Androstenedione (Congenital Adrenal Hyperplasia Treatment Panel)
  • Testosterone (Congenital Adrenal Hyperplasia Treatment Panel)